{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:40:45Z","timestamp":1787744445058,"version":"build-2784847793"},"reference-count":52,"publisher":"Baishideng Publishing Group Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Hepatol"],"DOI":"10.4254\/wjh.v15.i2.201","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T04:47:40Z","timestamp":1677214060000},"page":"201-207","source":"Crossref","is-referenced-by-count":41,"title":["Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis"],"prefix":"10.4254","volume":"15","author":[{"given":"Michael","family":"Kram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v8.i6.429"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.001"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i11.533"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i12.1436"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165888"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biology9110395"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15877"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32285"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00860-3"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020379"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13533"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04894-9"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02469-6"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153788"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2020.11.001"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-1022-4"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.744518"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15326"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09858-2"},{"key":"B20","doi-asserted-by":"crossref","unstructured":"Radhakrishnan A, Park K, Kwak IS, Jaabir M, Sivakamavalli J.   Classification of Lectins. In: Elumalai P, Lakshmi S. Lectins. Singapore: Springer, 2021","DOI":"10.1007\/978-981-16-7462-4_3"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.208884"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-020-09898-1"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03085-w"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13608"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511167103"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2014.00178"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i44.9706"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600392RR"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.151159"},{"key":"B30","unstructured":"Professor Bibek Gooptu.   Leicester Institute of Structural & Chemical Biology. [cited 11 August 2020]. Available from: https:\/\/m.youtube.com\/watch?v=PXfZr1KXjP8"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2019-BTSabstracts2019.95"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01169"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00558-8"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083481"},{"key":"B35","unstructured":"Goodman Z, Lowe E, Boudes P.   Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inflammatory Marker: An Immunohistochemical Survey. Proceedings of the American Association for the Study of Liver Diseases meetings; 2022 Nov; Washington, US"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00675-6"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143460"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.616044"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2128-8_15"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2009206117"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04971-z"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105881"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38497-8"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1894127"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030905"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwx071"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102622"},{"key":"B48","unstructured":"Galectin Therapeutics Inc.   A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment. [accessed 2022 Aug 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04332432 ClinicalTrials.gov Identifier: NCT04332432"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121585"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"B51","unstructured":"Galectin Therapeutics Inc.   Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis (NAVIGATE). [accessed 2022 Aug 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04365868 ClinicalTrials.gov Identifier: NCT04365868"},{"key":"B52","unstructured":"Galecto Therapeutics Inc.   Characterization of the Novel Galectin-3 inhibitor GB1107 on CCL4 induced liver fibrosis in mice. Proceedings of International Liver Congress; 2022 June; Leeds, UK. London"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i2\/201.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i2\/201.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T04:48:18Z","timestamp":1677214098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v15\/i2\/201.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":52,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.4254\/wjh.v15.i2.201","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,27]]}}}